Drug intelligence / Profile preview

KIND-039

Development stage: Preclinical
Lead developer: Elanco
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

KIND-039 is a fully caninized, high-affinity monoclonal antibody targeting interleukin-31 (IL-31) developed by Kindred Biosciences. It is engineered with a novel half-life extension technology, resulting in up to a three-fold longer half-life compared to tirnovetmab, another IL-31 antibody. This allows for significantly longer dosing intervals, potentially improving convenience and compliance for canine patients. KIND-039 is being developed as a long-acting therapy for atopic dermatitis and other dermatologic indications in dogs[1][5][9].

Targets

IL31 (IL-31)

Beyond the preview

Go deeper on KIND-039.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIND-039.

Explore the full profile